Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_09-cv-04980/USCOURTS-cand-3_09-cv-04980-3/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1332 Diversity-Account Receivable

---

`UNITED STATES DISTRICT COURT 

SOUTHERN DISTRICT OF ILLINOIS 

------------------------------------------------------------ X 

IN RE YASMIN AND YAZ 

(DROSPIRENONE) MARKETING, SALES 

PRACTICES AND RELEVANT PRODUCTS 

LIABILITY LITIGATION

------------------------------------------------------------ 

This Document Applies To All Actions 

: 

: 

: 

: 

: 

3:09-md-02100-DRH-PMF

MDL No. 2100 

Judge David R. Herndon

------------------------------------------------------------ X 

CASE MANAGEMENT ORDER NO. 9 

Agreed Order Regarding Direct Filing of Actions in the Southern District of Illinois and 

Service of Process in Cases Naming Particular Defendants

I. Scope of Order

This Order applies to claims brought by a U.S. citizen or resident based on 

ingestion or purchase of YAZ®, Yasmin® and Ocella that (i) currently are pending in MDL 

No. 2100 or (ii) will be filed in, removed to or transferred to this Court (collectively, “the MDL 

Proceedings”). 

II. Direct Filing of Cases in MDL 2100

A. In order to eliminate delays associated with transfer to this Court of cases filed in 

or removed to other federal district courts, and to promote judicial efficiency, any plaintiff whose 

case would be subject to transfer to MDL 2100 may file his or her case directly in the MDL 

Proceedings in the Southern District of Illinois. 

B. Each case filed directly in the MDL Proceedings by a plaintiff who resides in a 

federal district other than the Southern District of Illinois will be filed in the MDL Proceedings 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 1 of 8
2

for purposes of pretrial proceedings, consistent with the Judicial Panel on Multidistrict 

Litigation’s October 1, 2009 Transfer Order. 

C. Defendants will not challenge the venue of any action filed directly in the MDL 

Proceedings in the Southern District of Illinois for purposes of pretrial proceedings. Upon the 

completion of all pretrial proceedings applicable to a case directly filed in this Court pursuant to 

this Order, this Court, pursuant to 28 U.S.C. §1404(a), will transfer that case to the federal 

district court in the district where the plaintiff allegedly was injured by use of YAZ, Yasmin or 

Ocella or where the plaintiff resides at the time of such transfer. The parties will jointly advise 

the Court of the district to which each case should be transferred. 

D. Parts II.B. and II.C. do not preclude the parties from agreeing, at a future date, to 

try in this District certain cases filed pursuant to this Order. 

E. The inclusion of any action in In Re: Yasmin and Yaz (Drospirenone) Marketing, 

Sales Practices and Relevant Products Liability Litigation, MDL 2100, whether such action was 

or will be filed originally or directly in the Southern District of Illinois, shall not constitute a 

determination by this Court that jurisdiction or venue is proper in this District. 

F. The fact that a case was filed directly in the MDL Proceedings pursuant to this 

Order will have no impact on choice of law, including the statute of limitations that otherwise 

would apply to an individual case had it been filed in another district court and transferred to this 

Court pursuant to 28 U.S.C § 1407. 

G. The caption for any complaint that is directly filed in MDL 2100 before this Court 

shall bear the following caption: 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 2 of 8
3

UNITED STATES DISTRICT COURT 

SOUTHERN DISTRICT OF ILLINOIS 

------------------------------------------------------------ X 

IN RE YASMIN AND YAZ (DROSPIRENONE) 

MARKETING, SALES PRACTICES AND 

RELEVANT PRODUCTS LIABILITY 

LITIGATION 

------------------------------------------------------------ 

JANE DOE, 

 Plaintiff 

vs. 

XYZ CORPORATION and ABC COMPANY, 

 Defendants. 

: 

: 

: 

: 

: 

: 

: 

: 

: 

3:09-md-02100-DRH-CJP

MDL No. 2100 

Judge David R. Herndon 

COMPLAINT AND JURY DEMAND 

Civil Action No.: _______________ 

------------------------------------------------------------ X 

H. In accordance with the Initial Conference Order (Section 5.a), any attorney 

admitted to practice and in good standing in any United States District Court is admitted pro hac

vice in this litigation and association of co-counsel for purposes of litigation, including direct 

filing, is not required. 

I. Prior to any plaintiff’s lawyer filing a complaint directly in the United States 

District Court for the Southern District of Illinois, that attorney must register for and have an 

Illinois CM/ECF log in name and password. When filing a complaint in the Southern District of 

Illinois, an attorney must first request a case number by sending an email to: 

newcases_eaststlouis@ilsd.uscourts.gov. See CM/ECF Rule 4.0. Cases can only open during 

normal business hours Monday through Friday. All counsel shall allow the clerk at least 4 hours 

to open the file and are not to contact the clerk’s office with inquiries about a pending case 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 3 of 8
4

number unless special circumstances exist or if counsel has not received a case number within 24 

hours. 

J. The attorney who has electronically signed the complaint will receive an email 

notifying your office of the assigned case number. After plaintiff’s counsel receives the case 

number by email, the complaint can be filed. The system will ask whether there are any exhibits 

to the document, check “YES” and attach the civil cover sheet as an exhibit. 

K. When electronically filing the pleadings, the signature block shall follow the 

below format: 

RESPECTFULLY SUBMITTED, 

 

 /s/ Jane Doe 

Jane Doe 

NAME OF LAW FIRM 

ADDRESS 

TELEPHONE 

FAX 

EMAIL@EMAIL.com

Attorney for Plaintiff 

L. Filing Fees: Internet credit card payments shall be required for all complaints and 

are made online through Pay.gov. Plaintiff’s counsel will be prompted to pay the required filing 

fee at the time the complaint is filed. 

The Clerk’s Office will be electronically notified when the case is filed and will review 

for errors or omissions. After the complaint is filed, plaintiff’s counsel shall draft the 

summonses and send them to the Court by email to newcases_eaststlouis@ilsd.uscourts.gov. In 

the email, plaintiff’s counsel shall provide his or her name, the case number, and his or her 

mailing address. The clerk will file and send originals via mail-to the office of plaintiff’s so that 

plaintiff’s counsel can effectuate service of process. 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 4 of 8
5

III. Service of Process 

A. Bayer Schering Pharma AG admits that it manufactures drospirenone and ethinyl 

estradiol, the progestin and estrogen contained in YAZ, Yasmin and Ocella. Bayer HealthCare 

Pharmaceuticals Inc. admits that it markets YAZ and Yasmin in the United States. Some 

complaints list as defendants former names of Bayer Schering Pharma AG and Bayer HealthCare 

Pharmaceuticals Inc. 

1. Bayer Schering Pharma AG admits that it formerly was known as 

Schering AG and is the same corporate entity as Schering AG. 

2. Bayer HealthCare Pharmaceuticals Inc. admits that it was formerly 

known as Berlex, Inc., which formerly was known as Berlex Laboratories, Inc., 

and is the same corporate entity as Berlex, Inc. and Berlex Laboratories, Inc. 

Certain complaints name additional Bayer entities as defendants. The term “other Bayer 

entities,” as used herein, includes Schering AG, Berlex, Inc., Berlex Laboratories, Inc,, 

Bayer Corporation, Bayer HealthCare LLC, Bayer Pharmaceuticals Corporation, Bayer 

AG, Bayer HealthCare AG, Bayer Gesellschaft fur Beteiligungen mbH, and Bayer 

HealthCare Pharmaceuticals LLC. 

 B. Defendants Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering 

Pharma AG agree, without waiver of any defenses, to accept service of process pursuant 

to the terms of this Order in certain YAZ, Yasmin or Ocella cases commenced in, 

removed to, or transferred to this MDL. 

C. These procedures for informal service of process are not available in a case 

removed to federal court in which the plaintiff seeks remand to state court unless and until 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 5 of 8
6

remand is denied. All deadlines set forth in Part III of this Order run from the date on which 

remand is denied. 

D. Plaintiffs whose complaints are not subject to III.C and who have not already 

served Bayer Schering Pharma AG or Bayer HealthCare Pharmaceuticals Inc. through original 

process shall have ninety (90) days after the date of this Order or, for cases docketed hereafter, 

sixty (60) days after the date a case is docketed in this MDL, to serve the Complaint together 

with a Summons, as follows: 

1. By Certified Mail, Return Receipt Requested, upon the following 

representative of Bayer HealthCare Pharmaceuticals Inc.: 

SOP Department 

Corporation Service Company 

Suite 400 

2711 Centerville Road 

Wilmington, DE 19805 

2. By Registered Mail, Return Receipt Requested, upon the following 

representative of Bayer Schering Pharma AG: 

Eva Gardyan-Eisenlohr 

Head of Law & Patents 

Bayer Schering Pharma AG 

Müllerstrasse 178 

D- 13353 Berlin 

Germany 

3. A copy of each notice transmitted to any defendant in the foregoing 

manner also shall be emailed to yazservice@eckertseamans.com. 

E. Service will be effective only if addressed as above. General mailing to any 

defendant or use of other methods of transmission (e.g., Federal Express or DHL) will not be 

sufficient to effect service. Service will be effective ten (10) days after the date of delivery. 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 6 of 8
7

Other than those based on formal service of process, defendants reserve all other rights and 

defenses available to them under federal or state law and under applicable treaties and 

conventions. Prior to moving to dismiss a case for a defect in service under Parts III.D and III.E, 

defendants shall serve notice of the defect on plaintiff’s counsel and provide 30 days for plaintiff 

to cure the defect. 

F. The other Bayer entities are relieved of any obligation to answer complaints until 

further order of this Court. If plaintiffs believe that discovery demonstrates the involvement of 

one or more of the other Bayer entities in the subject matter of this litigation in a way that will 

require plaintiffs to pursue one or more of the other Bayer entities as defendants, plaintiffs shall 

meet and confer with defendants concerning whether discovery is required from those entities 

and, if no agreement is reached after meeting and conferring with the defendants, the parties 

shall seek the Court's guidance before plaintiffs commence any such discovery. 

G. For cases in which plaintiffs have served Bayer Healthcare Pharmaceuticals Inc., 

any applicable time limitations in Fed. R. Civ. P 4(m) are extended such that plaintiffs need not 

serve the other Bayer entities prior to January 3, 2011. Neither Bayer Schering Pharma AG, 

Bayer HealthCare Pharmaceuticals Inc., nor the other Bayer entities shall move to dismiss a 

complaint as to an unserved Bayer entity prior to January 31, 2011. 

IT IS SO ORDERED.

Signed this 18th day of February, 2010.

/s/ DavidRHer|do| 

Chief Judge United States District Court 

 

 

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 7 of 8
8

Case 3:09-cv-04980-SI Document 11 Filed 02/18/10 Page 8 of 8